Trenzyme
Trenzyme GmbH is a Konstanz-based CRO founded in 2000 that delivers custom recombinant protein production, cell line development, iPSC characterization and differentiation, and gene synthesis services to pharmaceutical, biotechnology, and academic customers worldwide under ISO 9001 quality standards.
- Company typePrivate
- Founded2000
- HeadquartersKonstanz, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Trenzyme does
Trenzyme GmbH is a privately held contract research organization (CRO) headquartered in Konstanz, Germany, founded in 2000 with a staff of 11-50 employees. The company delivers highly customized recombinant protein production and cell line development services to pharmaceutical, biotechnology, and academic customers worldwide, supporting projects from gene synthesis through to GMP-compliant Research Cell Banks. Its service catalog spans four expression platforms (E. coli, mammalian/HEK293, yeast, and insect cells), hiPSC characterization and differentiation into cardiomyocytes, neurons, microglia, hepatocytes, and monocytes, cell-based assay development, and gene synthesis with codon optimization, supplemented by off-the-shelf recombinant proteins and cell lines sold through its webshop.
Underlying technology centers on a modular vector and backbone toolbox of more than 300 validated expression constructs, an AI-driven target analysis layer added in 2024, a baculovirus-free insect cell expression system introduced the same year, and cGMP compliance options for production cell lines. All services are performed under an ISO 9001 quality management system audited by TÜV Süd, with additional certifications including BSFZ 2024 research bonus recognition and French Crédit d'Impôt Recherche eligibility. The portfolio is operated under standardized quality protocols but offered as modular, project-tailored packages rather than catalog SKUs.
Revenue is generated primarily through custom professional services contracts with individually quoted pricing, supported by project-anchor customers in large pharma (Boehringer Ingelheim, Roche, Takeda, Evonik, Idorsia) and a long tail of biotech, contract research, and academic buyers. Sales run through direct engagement (website contact form, [email protected], telephone) handled by scientific sales and application managers with a one-day response SLA; dedicated project managers provide weekly updates throughout execution. Off-the-shelf catalog revenue is incremental via shop.trenzyme.com. The company participates in industry events, publishes application notes, and maintains LinkedIn and YouTube presence for lead generation, with a documented stated emphasis on personalized scientific liaison as a competitive differentiator.
Trenzyme firmographics
Firmographics- Name
- Trenzyme
- Legal name
- trenzyme GmbH
- Website
- https://trenzyme.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Trenzyme GmbH is a Konstanz-based CRO founded in 2000 that delivers custom recombinant protein production, cell line development, iPSC characterization and differentiation, and gene synthesis services to pharmaceutical, biotechnology, and academic customers worldwide under ISO 9001 quality standards.
- Ownership category
- akta.pro rank
Trenzyme industry classification
Industry- Product category
- Contract Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
Keywords
Where Trenzyme is headquartered
LocationHeadquarters
- HQ city
- Konstanz
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Trenzyme business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Cell Culture Services: Project-based custom service contracts for stable cell line development, inducible expression cell lines, cell line expansion and adaption, GMP-compliant cell line development, stem cell characterization and differentiation, and cell-based assay development. Pricing is quote-based and customized per project.
- Protein Production Services: Custom recombinant protein production and purification services using E.coli, mammalian, yeast, and insect cell expression systems. Includes high-throughput screening and optimization services. Products also available off-the-shelf through their webshop.
- Gene Synthesis and Custom Cloning: Molecular biology services including gene synthesis with codon optimization, custom cloning, mutagenesis, and plasmid construction, offered as standalone services or bundled with downstream cell line and protein production services.
- Off-the-Shelf Products: Recombinant proteins and cell lines available for direct purchase through their webshop at shop.trenzyme.com for research use only.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom Project-Based Services |
| Unit Pricing | Pay-as-you-go | Off-the-Shelf Products |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
Trenzyme product offering
Product offeringCore offering
Trenzyme is a German biotech contract research organization founded in 2000 in Konstanz that provides custom cell line development, recombinant protein production, induced pluripotent stem cell (iPSC) characterization and differentiation, gene synthesis and cloning, and cell-based assay development services for pharmaceutical, biotechnology, and academic research clients. The company operates four expression systems (E. coli, mammalian, yeast, insect cells) and also distributes off-the-shelf recombinant proteins through an online webshop.
Product overview
Trenzyme offers a comprehensive portfolio of highly customized cell culture and protein production services as a research service provider. The core offerings include: Cell Line Services (stable cell line development, inducible expression systems, GMP-compliant development, expansion and adaptation); Stem Cell Services (hiPSC characterization and differentiation into functional cell types); Cell-Based Assay Services; and Protein Production Services (custom expression in E.coli, mammalian, insect, and yeast systems). Advanced offerings include AI-enhanced High-Throughput Protein Expression Screening with a modular vector toolbox of 300+ vectors. Supporting molecular biology services include Gene Synthesis and Custom Cloning. Products are available both as custom services and as off-the-shelf recombinant proteins and cell lines via their e-commerce shop. All services run under ISO 9001 quality management standards.
Differentiator
Problem solved
Functional benefit
Products and services
- Custom Cell Line Development Services Custom generation of stable, inducible, GMP-compliant, expansion, and adaption cell lines for pharmaceutical, biotechnology, and academic research clients using proprietary vector toolboxes and four expression hosts.
- Stem Cell Characterization and Differentiation Services Characterization and directed differentiation of induced pluripotent stem cells (iPSCs) for research clients in pharma, biotech, and academic settings.
- Cell-Based Assay Development Services Custom design and development of cell-based assays for drug discovery, functional genomics, and biological research applications.
- Custom Recombinant Protein Production Services Recombinant protein expression and purification across four production hosts (E. coli, mammalian, yeast, insect cells) with optional GMP compliance for pharma, biotech, and research customers.
- High-Throughput Protein Expression Screening High-throughput parallel screening of expression constructs and conditions, supported by AI-driven target analysis, to identify optimal protein production parameters.
- Gene Synthesis and Custom Cloning Services Custom gene synthesis with free codon optimization and downstream cloning into the customer's choice of vector, enabling a one-stop workflow from DNA design through to cell line generation.
- Off-the-Shelf Recombinant Proteins (Webshop) Standard, catalogue recombinant proteins available for direct purchase through the company's online webshop, with worldwide shipping for research use.
Quantifiable outcome
- 6,000+ successfully produced proteins and cell lines
- +2 more outcomes
Companies that use Trenzyme
Customer profileNamed customers16 records
Segments4 records
Ideal customer profiles3 records
Trenzyme technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability2 records
Feature5 records
Trenzyme partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered minor and core.
- Insel MainauminorSustainability partnership under discussion since 2023 for tree sponsorship and orchard care on Mainau Island, contributing to carbon offset and environmental compensation.
- Pan-BiotechminorPartnership since 2022 for media bottle recycling collection campaign. Recycled plastic is used to produce granulate for garden chairs, plastic bin liners, etc. Supports sustainability efforts.
- NMI - Naturwissenschaftliches und Medizinisches InstitutcoreR&D consortium partner in the PRADA project (Preclinical development of alpha-synuclein disaggregating therapeutic peptides for Parkinson's disease treatment). Trenzyme contributes predictive 3D human cell models and AI-based analysis methods.
- PriavoidcoreR&D consortium partner in PRADA project for developing all-D peptides to break down alpha-synuclein aggregates in Parkinson's disease.
- LMU MünchencoreAcademic R&D partner in PRADA project, contributing scientific expertise to the consortium.
- DLR - Deutsches Zentrum für Luft- und RaumfahrtcoreZIM-funded project partner developing rapid virus testing platform based on MIR laser spectroscopy in combination with protein-selective beads, using SARS-CoV-2 and Influenza A H1N1 as examples.
- Hahn-Schickard (nanodiagBW)coreR&D partner developing nanopore technology for molecular diagnostics of the future. Trenzyme develops production processes from gene to protein for various demanding targets.
- CyanagenminorEuroTransBio project partner for development of fluorescent molecular beacons for quantitative in situ detection of specific protein targets (2010-2013).
- Universität KonstanzminorEuroTransBio project partner for fluorescent molecular beacon development, bringing academic research expertise (2010-2013).
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Trenzyme competitors and assessment
Company assessmentBroad incumbents
- Lonza: Global CDMO with leading mammalian cell line development, GMP manufacturing, and biologics services — competing for Trenzyme's GMP-compliant cell line customers at substantially larger scale.
- Abcam: Research-reagent leader (now part of Danaher) with extensive recombinant protein and antibody offerings — competing with Trenzyme's webshop catalog and providing alternative supply for many biotech customers.
- Bio-Techne: Large life sciences tools company offering recombinant proteins, cell culture reagents, and cell line products — a broad incumbent competing with Trenzyme's catalog and custom protein services across multiple modalities.
- Catalent: Major CDMO offering cell line engineering, biologics development, and GMP manufacturing services — overlapping with Trenzyme's GMP-compliant cell line development work at larger commercial scale.
- Eurofins Scientific: Large global CRO offering an extensive portfolio including protein production, cell line development, and bioanalytical services — competing with Trenzyme at the high end while serving many other testing categories.
Direct peers
- ACROBiosystems: Specialist in recombinant protein production, with deep catalogs of off-the-shelf proteins and custom expression services across mammalian, E.coli, and insect systems — a direct comparable to Trenzyme's protein production and webshop offerings.
- Sino Biological: Major recombinant protein and gene CRO/CDMO serving pharma, biotech, and academic researchers worldwide with both catalog proteins and custom expression — directly comparable to Trenzyme in target customers and service mix.
- ATUM: Gene synthesis and protein expression services company (formerly DNA2.0) offering codon optimization and custom protein production — closely overlapping with Trenzyme's gene synthesis and expression optimization offerings.
- GenScript: Global life sciences CRO offering gene synthesis, recombinant protein expression, antibody services, and cell line development across multiple hosts — directly overlapping with Trenzyme's core service portfolio and competing for the same biotech and pharma customers.
- Miltenyi Biotec: Germany-headquartered cell biology specialist offering cell culture, cell line development, and iPSC-related products and services — a directly comparable European peer in cell culture and stem cell services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Trenzyme social profiles
Digital presenceTrenzyme compliance and trust
Trust signalCompliance2 records
Trenzyme financial estimates
Financial estimateRevenue estimate
Valuation estimate
Trenzyme leadership team
Management profileNumber of profiles
Profiles3 records
Trenzyme funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Trenzyme M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Trenzyme
What does Trenzyme do?
Trenzyme is a German biotech contract research organization founded in 2000 in Konstanz that provides custom cell line development, recombinant protein production, induced pluripotent stem cell (iPSC) characterization and differentiation, gene synthesis and cloning, and cell-based assay development services for pharmaceutical, biotechnology, and academic research clients. The company operates four expression systems (E. coli, mammalian, yeast, insect cells) and also distributes off-the-shelf recombinant proteins through an online webshop.
Is Trenzyme a public or private company?
Trenzyme is a private company. It is classified as family owned and is currently operating.
When was Trenzyme founded?
Trenzyme was founded in 2000. It employs 11 to 50 people.
Where is Trenzyme based?
Trenzyme is headquartered in Konstanz, Germany, in the Europe region.
How does Trenzyme make money?
Four revenue lines are on record. Cell Culture Services are the primary driver. The others are protein Production Services, gene Synthesis and Custom Cloning and off-the-Shelf Products.
Who are Trenzyme's main competitors?
Broad incumbents on record are Lonza, Abcam, Bio-Techne, Catalent and Eurofins Scientific. Direct peers are ACROBiosystems, Sino Biological, ATUM, GenScript and Miltenyi Biotec.
Does Trenzyme have an API?
No public API is recorded for Trenzyme.
What industry is Trenzyme in?
Trenzyme's product category is Contract Research Services. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 541714 and its SIC code is 2836.